The determination and correlation of molecular and cellular equilibrium Kd and kinetic koff values for small molecule allosteric antagonists of LFA-1

Biochemical Pharmacology

Volumn 74, Issue 1, 2007, Pages 98-106

  Caviness, Gary O ^a   Labadia, Mark E ^a   Giblin, Patricia A ^a   Woska Jr , Joseph R ^a   Last Barney, Kathleen ^a   Jeanfavre, Deborah D ^a   Morelock, Maurice M ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Adhesion molecules; Allosteric antagonists; Flow cytometry; Off rates; Receptor occupancy; SPR

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CELL ADHESION MOLECULE; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; INTERCELLULAR ADHESION MOLECULE 3; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1 BLOCKING AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 24; UNCLASSIFIED DRUG;

ALLOSTERISM; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BINDING SITE; CORRELATION ANALYSIS; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; KINETICS; MATHEMATICAL COMPUTING; PRIORITY JOURNAL;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANTIBODIES, MONOCLONAL; CELL ADHESION MOLECULES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HYDANTOINS; IMIDAZOLIDINES; INTEGRINS; INTERCELLULAR ADHESION MOLECULE-1; KINETICS; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; REPRODUCIBILITY OF RESULTS; SURFACE PLASMON RESONANCE;

EID: 34249017554     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.03.007     Document Type: Article

References (32)

1. Springer T.A. Adhesion receptors of the immune system. Nature 346 (1990) 425-434
2. Kishimoto T.K., Rothlein R., and Integrins. ICAMs, and selectins: role of regulation of adhesion molecules in neutrophil recruitment to inflammatory sites. Adv Pharmacol 25 (1994) 117-169
3. Hayflick J.S., Kilgannon P., and Gallatin W.M. The intercellular adhesion molecule (ICAM) family of proteins: New members and novel functions. Immunol Res 17 (1998) 313-327
4. Gottlieb A., Krueger J.G., Bright R., Ling M., Lebwohl M., Kang S., et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 42 (2000) 428-435
5. Gottlieb A.B., Krueger J.G., Wittkowski K., Dedrick R., Walicke P.A., and Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 138 (2002) 591-600
6. Gordon K.B., Papp K.A., Hamilton T.K., Walicke P.A., Dummer W., Li N., Bresnahan B.W., et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290 (2003) 3073-3080
7. Lebwohl M., Tyring S.K., Hamilton T.K., Toth D., Glazer S., Tawfik N.H., et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349 (2003) 2004-2013
8. Vugmeyster Y., Kikuchi T., Lowes M.A., Chamian F., Kagen M., Gilleaudeau P., et al. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol 113 (2004) 38-46
9. Leonardi C.L., Papp K.A., Gordon K.B., Menter A., Feldman S.R., Caro I., et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 52 (2005) 425-433
10. Menter A., Gordon K., Carey W., Hamilton T., Glazer S., Caro I., et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141 (2005) 31-38
11. Giblin P.A., and Lemieux R.M. LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics. Curr Pharm Des 12 (2006) 2771-2795
12. Randi A.M., and Hogg N. I domain of beta 2 integrin lymphocyte function-associated antigen-1 contains a binding site for ligand intercellular adhesion molecule-1. J Biol Chem 269 (1994) 12395-12398
13. Miller J., Knorr R., Ferrone M., Houdei R., Carron C.P., and Dustin M.L. Intercellular adhesion molecule-1 dimerization and its consequences for adhesion mediated by lymphocyte function-associated antigen-1. J Exp Med 182 (1995) 1231-1241
14. Woska Jr. J.R., Morelock M.M., Jeanfavre D.D., and Bormann B.J. Characterization of molecular interactions between intercellular adhesion molecule-1 and leukocyte function-associated antigen-1. J Immunol 156 (1996) 4680-4685
15. Labadia M.E., Jeanfavre D.D., Caviness G.O., and Morelock M.M. Molecular regulation of the interaction between Leukocyte-Associated Antigen-1 and soluble ICAM-1 by divalent metal cations. J Immunol 161 (1998) 836-842
16. Shimaoka M., Lu C., Palframan R.T., von Adrian U.H., McCormack A., Takagi J., et al. Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin alphaL I domains with high affinity and antagonist activity in vivo. Proc Natl Acad Sci USA 98 (2001) 6009-6014
17. 2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity 19 (2003) 391-402
18. Shimaoka M., Xiao T., Liu J., Yang Y., Dong Y., Jun C., et al. Structures of the αL I domain and it's complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 112 (2003) 99-111
19. Lollo B.A., Chan K.W.H., Hanson E.M., Moy V.T., and Brian A.A. Direct evidence for two affinity states for lymphocyte function-associated antigen 1 on activated T cells. J Bio Chem 268 (1993) 21693-21700
20. Lu C., Shimaoka M., Zang Q., Takagi J., and Springer T.A. Locking in alternate conformations of the integrin alphaLbeta2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc Natl Acad Sci USA 98 (2001) 2393-2398
21. Lu C., Shimaoka M., Ferzly M., Oxvig C., Takagi J., and Springer T.A. An isolated, surface-expressed I domain of the integrin alphaLbeta2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond. Proc Natl Acad Sci USA 98 (2001) 2387-2392
22. Kelly T.A., Jeanfavre D.D., McNeil D.W., Woska Jr. J.R., Reilly P.L., Mainolfi E.A., et al. Cutting Edge: A small molecule antagonist of LFA-1-mediated cell adhesion. J Immunol 163 (1999) 5173-5177
23. Last-Barney K., Davidson W., Cardoza M., Frye L.L., Grygon C.A., Hopkins J.L., et al. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein:protein interaction. J Am Chem Soc 123 (2001) 5643-5650
24. Woska Jr. J.R., Shih D., Taqueti V.R., Hogg N., Kelly T.A., and Kishimoto T.K. A small-molecule antagonist of LFA-1 blocks a conformational change important for LFA-1 function. J Leuk Biol 70 (2001) 329-334
25. Argenbright L.W., Letts L.G., and Rothlein R. Monoclonal antibodies to the leukocyte membrane CD18 glycoprotein complex and to intercellular adhesion molecule-1 inhibit leukocyte-endothelial adhesion in rabbits. J Leuk Biol 49 (1991) 253-257
26. Woska Jr. J.R., Morelock M.M., Jeanfavre D.D., Caviness G.O., Bormann B.J., and Rothlein R. Molecular comparison of soluble intercellular adhesion molecule (sICAM)-1 and sICAM-3 binding to lymphocyte function-associated antigen-1. J Biol Chem 273 (1998) 4725-4733
27. Wu J.P., Emeigh J., Gao D.A., Goldberg D.R., Kuzmich D., Miao C., et al. Second-generation lymphocyte function-associated antigen-1 inhibitors: 1H-Imidazo [1,2-α] imidazol-2-one derivatives. J Med Chem 47 (2004) 5356-5366
28. Dustin M.L., Carpen O., and Springer T.A. Regulation of locomotion and cell-cell contact area by the LFA-1 and ICAM-1 adhesion receptors. J Immunol 148 (1992) 2654-2663
29. Johnsson B., Löfås S., and Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem 198 (1991) 268-277
30. Morelock M.M., Ingraham R., Betageri R., and Jakes S. Determination of receptor-ligand kinetic and equilibrium binding constants using surface plasmon resonance: Application to the lck SH2 domain and phosphotyrosyl peptides. J Med Chem 38 (1995) 1309-1318
31. Woska Jr. J.R., Last-Barney K., Rothlein R., Kroe R.R., Reilly P.L., Jeanfavre D.D., et al. Small molecule LFA-1 antagonists compete with an anti-LFA-1 monoclonal antibody for binding to the CD11a I domain: Development of a flow-cytometry-based receptor occupancy assay. J Immunol Meth 277 (2003) 101-115
32. Stewart M., and Hogg N. Regulation of leukocyte integrin function: Affinity vs. Avidity. J Cell Biochem 61 (1996) 554-561